Nov, 17th 2020 – A new vaccine that protects against Covid-19 is nearly 95% effective. The results from the US Company moderna are similar to those of Pfizer and BioNtech proving that vaccines can help end the pandemic. Moderna now says that they plan to apply for approval to use the vaccine in the next few weeks. If approved for use, the availability of the vaccine shall depend on the geographic location of the patient globally as well as their age.
This is a new hope as there is promising race for a Covid-19 vaccine as infections spike across the United States and Europe. In a statement, Moderna’s CEO Stephane Bancel said, “This is a pivotal moment in the development of our COVID-19 vaccine candidate. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.“
This news comes after announcements from the US drug giant Pfizer that phase three trial results for the Covid-19 vaccin it is developing with Germany’s BioNTech showed it to be 90 percent effective. These results place both Moderna and Pfizer on track to seek approval from the US Food and Drug Administration for emergency use in the coming weeks.
If they get approved, supplies of both the vaccines is limited and rationed before the end of the year. Both the vaccines require an indiviidual to take two shots two months apart.
Moderna expects to have about 220 million dozes reserved for the US by the end of 2020. On the other hand, Pfizer and BioNTech expect to have about 50 million dozes globally by year end. Responding to the news on Twitter, US Secretary of Health and Human Service Alex Azhar said, “This news is another stunning result of President Trump’s leadership and his unwavering support for #OperationWarpSpeed, an incredible tribute to American scientists and innovators, and one more reminder that there is light at the end of the tunnel.”
Expressing his delight on Twitter, Pfizer CEO Albert Bouria said on Twitter that he is thrilled by Moderna’s trial result saying, “Our companies share a common goal -defeating this dreaded disease – and today we congratulate everyone at Moderna and share in the joy of their encouraging results.”
Unlike how vaccines are created from the virus, these two vaccines are not made with the coronavirus itself so there is no chance that anyone could catch the virus from the shots. The vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.